AVAI Bio Posts $552K Quarterly Loss, Cash Rises to $84K, Going Concern Lingers
AVAI is trading near its 52-week low of $0.11 (8.7% above the low).
Summary
AVAI Bio's quarterly report shows a widening loss, no revenue, and a growing working capital deficit, though cash improved slightly. Going concern risk remains high.
Key Events · Earnings and Guidance · AVAI
-
Net Loss Widens
For the three months ended June 30, 2026, the net loss was $552,041, up from $487,589 in the prior-year quarter, driven by $132,258 in other expenses including interest and a loss on disposal of a subsidiary.
-
Cash Improves but Liabilities Grow
Cash increased to $83,586 from $23,145 at March 31, 2026, but total liabilities rose to $4,014,316 and the working capital deficit widened to $3,860,035.
-
Going Concern Warning Reiterated
Management states there is substantial doubt about the company's ability to continue as a going concern, with no revenue and recurring losses.
-
New Financing and Debt
The company issued new convertible notes and loans payable during the quarter, including a $58,600 promissory note for the Wellness Assessment API acquisition.
Analysis · AVAI · Technology
The Q1 FY2027 10-Q from AVAI Bio reveals a net loss of $552,041, up from $487,589 a year earlier, with no revenue. Cash improved to $83,586 from $23,145 at fiscal year-end, but total liabilities climbed to $4.0 million and the working capital deficit widened to $3.86 million. Substantial doubt about the company's ability to continue as a going concern is reiterated, and new convertible notes and loans are disclosed. The filing also reveals the dissolution of the Ai-Nova joint venture and a $58,600 API acquisition.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVAI was trading at $0.12 on OTC in the Technology sector, with a market capitalization of approximately $18.5M. The 52-week trading range was $0.11 to $0.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.